Table 1.
Demographic data for 105 patients in PPK model
| Variable | Valuesa |
|---|---|
| Demographics | |
| Age (years) | 65 (IQR: 55, 76) |
| Gender (male) | 76 (72.4%) |
| Weight (Kg) | 55.0 (IQR:50.0, 65.0) |
| Clinical condition | |
| Albumin (g/L) | 30.7 (IQR: 27.9, 34.2) |
| Baseline creatinine clearance (mL/min) | 72.2 (IQR: 50.5, 111.5) |
| Baseline BUN (mmol/L) | 9.8 (IQR: 6.6, 15.8) |
| Mechanical ventilation | 81 (77.1%) |
| APACHEII scores | 18 (IQR: 12, 25) |
| Mortality rates | 28 (26.7%) |
| Comorbidities | |
| Sepsis | 41 (39.0%) |
| Pulmonary diseases | 15 (14.3%) |
| Heart disease | 58 (55.2%) |
| Diabetes mellitus | 19 (18.1%) |
| Chronic liver disease | 29 (27.6%) |
| Chronic renal dysfunction | 25 (23.8%) |
| Trauma | 5 (4.8%) |
| Solid tumor | 15 (14.3%) |
| Pathogens | |
| CRAB | 86 (81.9%) |
| CRKP | 42 (40.0%) |
| CRPA | 23 (21.9%) |
| PMB treatment | |
| PMB loading dose (mg) (n = 87) | 100 (IQR: 100, 150) |
| PMB loading dose (mg/kg) (n = 87) | 2.1 (IQR: 1.9, 2.3) |
| PMB daily dose (mg) | 150 (IQR: 100, 150) |
| PMB daily dose by weight (mg/kg/day) | 2.3 (IQR: 2.0, 2.9) |
| PMB treatment duration (days) | 12 (IQR: 9, 16) |
| PMB total dose (mg) | 1500 (IQR: 1100, 2175) |
| PMB total dose by weight (mg/kg/day) | 26.0 (IQR: 18.7, 38.2) |
| Combinational therapy | |
| Carbepenem | 36 (34.3%) |
| Tigecycline | 33 (31.4%) |
| Other β-lactam antibioticsb | 32 (30.5%) |
| Ceftazidime avibactam | 4 (3.8%) |
| Quinolone | 4 (3.8%) |
IQR Interquartile range, APACHE Acute physiology and chronic health evaluation, BUN Blood urea nitrogen. PMB Polymyxin B, CRAB Carbapenem-resistant acinetobacter baumannii, CRKP Carbapenem-resistant klebsiella pneumonia, CRPA Carbapenem-resistant pseudomonas aeruginosa
aCategorical data are number (%) of subjects, continuous data are expressed as median (interquartile range, IQR)
bother β-lactam antibiotics include cefoperazone/sulbactam (n = 23) and piperacillin/tazobactam (n = 9)